Skip to content

The Combination Effect of Dexmedetomidine and Morphine in Postoperative Patient-Controlled Analgesia

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00800826
Enrollment
150
Registered
2008-12-02
Start date
2006-11-30
Completion date
2008-04-30
Last updated
2008-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Patient-Controlled, Analgesia, Postoperative

Brief summary

This study was designed to examine the analgesic and side effects of dexmedetomidine-morphine mixture for intravenous patient-controlled analgesia (PCA).

Detailed description

Patient-controlled analgesia (PCA) is a widely accepted method to control postoperative pain. Morphine is the commonest opioid for PCA, however its side effects are troublesome. Morphine-related side effects include pruritus, nausea, vomiting, constipation, urinary retention, respiratory depression, and sedation. Many studies had been conducted to reduce the side effect of morphine. The current trend of reducing morphine side effect is direct combination of other drugs and morphine in PCA. The advantages of this method are convenient in clinical use and preventive for side effects. Dexmedetomidine is a highly selec¬tive α2-adrenergic receptor agonist that has been reported to cause sedative effects and reduce opioid requirements in the perioperative period. The main advantage of this drug is that it does not cause serious respiratory side effects. The analgesic, sedative/hypnotic and anxiolytic prop¬erties of dexmedetomidine make this drug potentially useful for postoperative sedation and analgesia. No previous study had investigated the effect of direct combination of dexmedetomidine and morphine in PCA. The goal of this study is to investigate the combination effect of dexmedetomidine and morphine in postoperative patient-controlled analgesia.

Interventions

DRUGdexmedetomidine

Sponsors

National Taiwan University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Patients who sign informed consent to receive general anesthesia and postoperative analgesia with a PCA device 2. Age between 18-65 y/o 3. ASA physical status I-III 4. Scheduled surgical procedures: gynecological surgery (vaginal or abdominal total hysterectomy), general surgery (gastrectomy, hepatectomy, colon cancer) , orthopedic (spinal fusion or total knee placement), or neurosurgical (cervical decompression)

Exclusion criteria

1. Patients with a definite diagnosis of chronic pain syndrome, psychiatric disorders, or drug abuse (include opioids, NSAIDs, sedatives, antidepressants). 2. Use of sedatives, analgesics, antiemetics, or antipruritics within 24 hours before operation. 3. Patients with definite diagnosis of esophageal reflux syndrome. 4. Patients with the probability to be pregnant. 5. Intraoperative fentanyl use \> 6 μg/kg. 6. Patients with significant bradycardia (HR \< 60/min) and hypotension (SBP \< 90mmHg) after the surgery. 7. The duration of surgery is longer than 6 hours.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026